1-20 of 31
Hui Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening

Available to Purchase
Karl J. Habashy, Timothy W. Synold, Ye Feng, Cristal Gomez, Christina Amidei, Rachel Ward, Sarah VanderMolen, Ashkan Zarrieneh, Kwang-Soo Kim, Mateo Gomez, Victor A. Arrieta, Jawad Fares, Kirsten B. Burdett, Hui Zhang, Crismita Dmello, Li Chen, John F. Bebawy, Michael Canney, Roger Stupp, Behnam Badie, Jana Portnow, Adam M. Sonabend
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF9.
https://doi.org/10.1158/1078-0432.CCR-25-0080
Published: 01 July 2025
View article titled, Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
Open the PDF for Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening in another window
Includes: Supplementary data
Journal Articles

Abstract P5-03-14: Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting

Free
Yuxin Mu, Hui Zhang, Chao Deng, Jiao Yang, Lu Gan, Qingmo Yang, Xuefeng Xu, Wanping Liang, Xiaowei Qi, Liang Xu, Jian Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P5-03-14.
https://doi.org/10.1158/1557-3265.SABCS24-P5-03-14
Published: 13 June 2025
View article titled, Abstract P5-03-14: Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting
Journal Articles

Abstract P5-07-14: Clinical study of 99mTc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer

Free
Hui Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P5-07-14.
https://doi.org/10.1158/1557-3265.SABCS24-P5-07-14
Published: 13 June 2025
View article titled, Abstract P5-07-14: Clinical study of 99mTc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
Journal Articles

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Available to Purchase
Michael H. Brave, William F. Maguire, Chana Weinstock, Hui Zhang, Xin Gao, Fang Li, Jingyu Yu, Wentao Fu, Hong Zhao, William F. Pierce, Elaine Chang, Jeannette Dinin, Mallorie H. Fiero, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri-Kordestani, Daniel L. Suzman
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4815–4821.
https://doi.org/10.1158/1078-0432.CCR-24-1393
Published: 01 November 2024
View article titled, FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
Open the PDF for FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma

Available to Purchase
Karl J. Habashy, Crismita Dmello, Li Chen, Victor A. Arrieta, Kwang-Soo Kim, Andrew Gould, Mark W. Youngblood, Guillaume Bouchoux, Kirsten B. Burdett, Hui Zhang, Michael Canney, Roger Stupp, Adam M. Sonabend
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1619–1629.
https://doi.org/10.1158/1078-0432.CCR-23-2367
Published: 15 April 2024
View article titled, Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma
Open the PDF for Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma in another window
Includes: Supplementary data
Journal Articles

ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis

Available to Purchase
Víctor A. Arrieta, Johnny Duerinck, Kirsten B. Burdett, Karl J. Habashy, Wietse Geens, Andrew Gould, Julia K. Schwarze, Crismita Dmello, Kwang-Soo Kim, Ruth Saganty, Li Chen, Alberto Moscona, Matthew McCord, Catalina Lee-Chang, Craig M. Horbinski, Hui Zhang, Roger Stupp, Bart Neyns, Adam M. Sonabend
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 379–388.
https://doi.org/10.1158/1078-0432.CCR-23-1889
Published: 17 January 2024
View article titled, ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis
Open the PDF for ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis in another window
Includes: Supplementary data
Journal Articles

Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data

Open Access
Munawar Anwar, Qitong Chen, Dengjie Ouyang, Shouman Wang, Ning Xie, Quchang Ouyang, Peizhi Fan, Liyuan Qian, Gannong Chen, Enxiang Zhou, Lei Guo, Xiaowen Gu, Boning Ding, Xiaohong Yang, Liping Liu, Chao Deng, Zhi Xiao, Jing Li, Yunqi Wang, Shan Zeng, Jinhui Hu, Wei Zhou, Bo Qiu, Zhongming Wang, Jie Weng, Mingwen Liu, Yi Li, Tiegang Tang, Jianguo Wang, Hui Zhang, Bin Dai, Wuping Tang, Tao Wu, Maoliang Xiao, Xiantao Li, Hailong Liu, Lai Li, Wenjun Yi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4634–4641.
https://doi.org/10.1158/1078-0432.CCR-21-0474
Published: 15 August 2021
View article titled, Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Open the PDF for Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data in another window
Includes: Supplementary data
Journal Articles

Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia

Available to Purchase
Hui Zhang, Pengfei Wang, Zhuoyan Li, Yingyi He, Wenting Gan, Hua Jiang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3549–3555.
https://doi.org/10.1158/1078-0432.CCR-20-4543
Published: 01 July 2021
View article titled, Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia
Open the PDF for Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer

Available to Purchase
Ning Li, Hualei Bu, Jihong Liu, Jianqing Zhu, Qi Zhou, Li Wang, Rutie Yin, Xiaohua Wu, Shuzhong Yao, Kangsheng Gu, Hui Zhang, Guiling Li, Hongming Pan, Qiang Wu, Ruifang An, Xinfeng Yang, Yaping Zhu, Xiaoping Wan, Wei Duan, Jianping Xiong, Hongyan Guo, Ge Lou, Jing Wang, Wenjing Hu, Xin Zhang, Yuanguang Meng, Ben Zhang, Yuting Wang, Quanren Wang, Lingying Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2452–2458.
https://doi.org/10.1158/1078-0432.CCR-20-3546
Published: 01 May 2021
View article titled, An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Open the PDF for An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer

Available to Purchase
Jennifer J. Gao, Christy L. Osgood, Yutao Gong, Hui Zhang, Erik W. Bloomquist, Xiling Jiang, Junshan Qiu, Jingyu Yu, Pengfei Song, Nam Atiqur Rahman, Haw-Jyh Chiu, Tiffany K. Ricks, Fatima Rizvi, Sherry Hou, Willie Wilson, Abde M. Abukhdeir, Jeffrey Seidman, Soma Ghosh, Reena Philip, William F. Pierce, Vishal Bhatnagar, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2126–2129.
https://doi.org/10.1158/1078-0432.CCR-20-3474
Published: 15 April 2021
View article titled, FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
Open the PDF for FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer in another window
Journal Articles

Abstract PR-002: SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation

Free
Elizabeth V. Minten, Priya Kappor-Vazirani, Chunyang Li, Hui Zhang, Kamakshi Balakrishnan, David S. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8_Supplement): PR-002.
https://doi.org/10.1158/1557-3265.RADSCI21-PR-002
Published: 15 April 2021
View article titled, Abstract PR-002: SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation
Journal Articles

Abstract PO-049: TGFβ and PD-L1 inhibition in combination with radiotherapy can overcome glioblastoma resistance to immunotherapies

Free
Oliver Reiners, Ann Lazar, William Chou, Hui Zhang, Trevor Jones, Dixon Hoffelt, Mary Helen Barcellos-Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8_Supplement): PO-049.
https://doi.org/10.1158/1557-3265.RADSCI21-PO-049
Published: 15 April 2021
View article titled, Abstract PO-049: TGFβ and PD-L1 inhibition in combination with radiotherapy can overcome glioblastoma resistance to immunotherapies
Journal Articles

Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study

Available to Purchase
Yuxi Yi, Lijun Shen, Wei Shi, Fan Xia, Hui Zhang, Yan Wang, Jing Zhang, Yaqi Wang, Xiaoyang Sun, Zhiyuan Zhang, Wei Zou, Wang Yang, Lingyi Zhang, Ji Zhu, Ajay Goel, Yanlei Ma, Zhen Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1329–1340.
https://doi.org/10.1158/1078-0432.CCR-20-3445
Published: 01 March 2021
View article titled, Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study
Open the PDF for Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study in another window
Includes: Supplementary data
Journal Articles

TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas

Available to Purchase
Koushik Muralidharan, Anudeep Yekula, Julia L. Small, Zachary S. Rosh, Keiko M. Kang, Lan Wang, Spencer Lau, Hui Zhang, Hakho Lee, Chetan Bettegowda, Michael R. Chicoine, Steven N. Kalkanis, Ganesh M. Shankar, Brian V. Nahed, William T. Curry, Pamela S. Jones, Daniel P. Cahill, Leonora Balaj, Bob S. Carter
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 169–178.
https://doi.org/10.1158/1078-0432.CCR-20-3083
Published: 04 January 2021
View article titled, TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Open the PDF for TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas in another window
Includes: Supplementary data
Journal Articles

ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia

Available to Purchase
Heng Xu, Xujie Zhao, Deepa Bhojwani, Shuyu E, Charnise Goodings, Hui Zhang, Nita L. Seibel, Wentao Yang, Chunliang Li, William L. Carroll, William E. Evans, Jun J. Yang
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 256–264.
https://doi.org/10.1158/1078-0432.CCR-19-0190
Published: 03 January 2020
View article titled, ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia
Open the PDF for ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract NT-112: APTAMER CONJUGATED NANOPARTICLES FOR TARGETED DRUG DELIVERY

Free
Varatharasa Thiviyanathan, Fengmei Pi, Hui Zhang, Hui Li, Hongyu Wang, Peixuan Guo, Anil Sood
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): NT-112.
https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-112
Published: 15 November 2019
View article titled, Abstract NT-112: APTAMER CONJUGATED NANOPARTICLES FOR TARGETED DRUG DELIVERY
Journal Articles

Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission

Free
Meng Lv, Yu Wang, Ying-Jun Chang, Xiao-Hui Zhang, Lan-Ping Xu, Qian Jiang, Hao Jiang, Jin Lu, Huan Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Yao Chen, Chen-Hua Yan, Yuan-Yuan Zhang, Yu-Qian Sun, Xiao-Dong Mo, Hong-Hu Zhu, Jin-Song Jia, Ting Zhao, Jing Wang, Kai-Yan Liu, Xiao-Jun Huang
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1737–1748.
https://doi.org/10.1158/1078-0432.CCR-18-1637
Published: 15 March 2019
View article titled, Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission
Open the PDF for Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission in another window
Includes: Supplementary data
Journal Articles

Development and Validation of a Novel Signature to Predict Overall Survival in “Driver Gene–negative” Lung Adenocarcinoma (LUAD): Results of a Multicenter Study

Free
Yongmei Cui, Wenfeng Fang, Chaofeng Li, Kejing Tang, Jian Zhang, Yiyan Lei, Weiling He, Sui Peng, Ming Kuang, Hui Zhang, Lili Chen, Di Xu, Cuilan Tang, Wenhui Zhang, Yuxin Zhu, Wenting Jiang, Neng Jiang, Yu Sun, Yangshan Chen, Han Wang, Yingrong Lai, Shuhua Li, Qiong He, Jianwen Zhou, Yang Zhang, Millicent Lin, Honglei Chen, Chenzhi Zhou, Chunlin Wang, Jianhong Wang, Xuenong Zou, Liantang Wang, Zunfu Ke
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (5): 1546–1556.
https://doi.org/10.1158/1078-0432.CCR-18-2545
Published: 01 March 2019
View article titled, Development and Validation of a Novel Signature to Predict Overall Survival in “Driver Gene–negative” Lung Adenocarcinoma (LUAD): Results of a Multicenter Study
Open the PDF for Development and Validation of a Novel Signature to Predict Overall Survival in “Driver Gene–negative” Lung Adenocarcinoma (LUAD): Results of a Multicenter Study in another window
Includes: Supplementary data
Journal Articles

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Free
Lan V. Pham, Shengjian Huang, Hui Zhang, Jun Zhang, Taylor Bell, Shouhao Zhou, Elizabeth Pogue, Zhiyong Ding, Laura Lam, Jason Westin, R. Eric Davis, Ken H. Young, L. Jeffrey Medeiros, Richard J. Ford, Krystle Nomie, Leo Zhang, Michael Wang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (16): 3967–3980.
https://doi.org/10.1158/1078-0432.CCR-17-3004
Published: 14 August 2018
View article titled, Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Open the PDF for Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Free
Leo Zhang, Krystle Nomie, Hui Zhang, Taylor Bell, Lan Pham, Sabah Kadri, Jeremy Segal, Shaoying Li, Shouhao Zhou, David Santos, Shawana Richard, Shruti Sharma, Wendy Chen, Onyekachukwu Oriabure, Yang Liu, Shengjian Huang, Hui Guo, Zhihong Chen, Wenjing Tao, Carrie Li, Jack Wang, Bingliang Fang, Jacqueline Wang, Lei Li, Maria Badillo, Makhdum Ahmed, Selvi Thirumurthi, Steven Y. Huang, Yiping Shao, Laura Lam, Qing Yi, Y. Lynn Wang, Michael Wang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4212–4223.
https://doi.org/10.1158/1078-0432.CCR-16-2703
Published: 01 August 2017
View article titled, B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Open the PDF for B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy in another window
Includes: Supplementary data